Phase II study of 21 day schedule oral etoposide in children. New Agents Group of the United Kingdom Children's Cancer Study Group (UKCCSG).
about
Phase II study of cisplatin and oral VP16 in patients with refractory or relapsed Ewing sarcoma.Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapySignificant response to oral Etoposide in the treatment of an unresectable cardiac sarcoma.Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives.Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?Metronomics: towards personalized chemotherapy?A Phase II feasibility study of oral etoposide given concurrently with radiotherapy followed by dose intensive adjuvant chemotherapy for children with newly diagnosed high-risk medulloblastoma (protocol POG 9631): A report from the Children's OncoloA phase II study to determine the efficacy and safety of oral treosulfan in patients with advanced pre-treated Ewing sarcoma ISRCTN11631773.Bioavailability and pharmacokinetic features of etoposide in childhood acute lymphoblastic leukemia patients.Oral etoposide for recurrent/progressive sarcomas of childhood.Low-dose oral etoposide-based induction regimen for children with acute lymphoblastic leukemia in first bone marrow relapse.The use of palliative chemotherapy in pediatric oncology patients: a national survey of pediatric oncologists.Relapse in medulloblastoma: what can be done after abandoning high-dose chemotherapy? A mono-institutional experience.
P2860
Q33404428-3D1E161C-FCA0-4EEE-BED5-45C249F82D66Q35008766-6632F3FB-B8DC-456E-9A5C-8D61D306ECBAQ35776827-271926C0-7BAA-497B-98C8-84B468A07440Q37528441-E3E2E560-BAD0-42A2-8885-B555A7EFAA8BQ37834445-C1FE539F-4391-41F4-86CF-3081EF568FC7Q38218923-53905235-5BC7-409A-A300-CAB4E4B95C7BQ39078623-EE9B00B3-3EA2-49E3-AA9C-29C47D7C0FC9Q39118505-994F604B-A43D-4BCA-9705-9849759BE85FQ43792801-0FCA640C-7962-4287-BC9E-DBF8EE4DE2F2Q44766160-15DC0C43-9CF8-46BC-B65B-5BE787F0664FQ45051066-E14A0240-CC09-4C40-B391-DB504D4503ADQ45193912-BB920B2E-8E75-4C85-A634-DD50740129AFQ48258994-391ED270-A21A-4F87-BE6F-2AAB8B4F9356
P2860
Phase II study of 21 day schedule oral etoposide in children. New Agents Group of the United Kingdom Children's Cancer Study Group (UKCCSG).
description
1997 nî lūn-bûn
@nan
1997 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Phase II study of 21 day sched ...... s Cancer Study Group (UKCCSG).
@ast
Phase II study of 21 day sched ...... s Cancer Study Group (UKCCSG).
@en
type
label
Phase II study of 21 day sched ...... s Cancer Study Group (UKCCSG).
@ast
Phase II study of 21 day sched ...... s Cancer Study Group (UKCCSG).
@en
prefLabel
Phase II study of 21 day sched ...... s Cancer Study Group (UKCCSG).
@ast
Phase II study of 21 day sched ...... s Cancer Study Group (UKCCSG).
@en
P2093
P1476
Phase II study of 21 day sched ...... s Cancer Study Group (UKCCSG).
@en
P2093
Davidson A
Dicks-Mireaux C
Pinkerton CR
P304
P356
10.1016/S0959-8049(97)00201-3
P577
1997-10-01T00:00:00Z